Collegium Pharmaceutical (COLL) Competitors $27.12 +0.39 (+1.46%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$27.14 +0.02 (+0.07%) As of 04/15/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock COLL vs. RYTM, PTCT, OGN, ZLAB, ACLX, RNA, RARE, AKRO, MOR, and SWTXShould you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Organon & Co. (OGN), Zai Lab (ZLAB), Arcellx (ACLX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Akero Therapeutics (AKRO), MorphoSys (MOR), and SpringWorks Therapeutics (SWTX). These companies are all part of the "pharmaceutical products" industry. Collegium Pharmaceutical vs. Rhythm Pharmaceuticals PTC Therapeutics Organon & Co. Zai Lab Arcellx Avidity Biosciences Ultragenyx Pharmaceutical Akero Therapeutics MorphoSys SpringWorks Therapeutics Rhythm Pharmaceuticals (NASDAQ:RYTM) and Collegium Pharmaceutical (NASDAQ:COLL) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, community ranking, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk. Does the MarketBeat Community prefer RYTM or COLL? Collegium Pharmaceutical received 81 more outperform votes than Rhythm Pharmaceuticals when rated by MarketBeat users. However, 68.06% of users gave Rhythm Pharmaceuticals an outperform vote while only 65.44% of users gave Collegium Pharmaceutical an outperform vote. CompanyUnderperformOutperformRhythm PharmaceuticalsOutperform Votes30968.06% Underperform Votes14531.94% Collegium PharmaceuticalOutperform Votes39065.44% Underperform Votes20634.56% Is RYTM or COLL more profitable? Collegium Pharmaceutical has a net margin of 14.78% compared to Rhythm Pharmaceuticals' net margin of -230.07%. Collegium Pharmaceutical's return on equity of 104.67% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-230.07% -367.36% -77.47% Collegium Pharmaceutical 14.78%104.67%18.38% Do analysts prefer RYTM or COLL? Rhythm Pharmaceuticals presently has a consensus price target of $74.92, suggesting a potential upside of 20.67%. Collegium Pharmaceutical has a consensus price target of $43.60, suggesting a potential upside of 60.77%. Given Collegium Pharmaceutical's higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than Rhythm Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 3.00Collegium Pharmaceutical 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media favor RYTM or COLL? In the previous week, Rhythm Pharmaceuticals had 15 more articles in the media than Collegium Pharmaceutical. MarketBeat recorded 29 mentions for Rhythm Pharmaceuticals and 14 mentions for Collegium Pharmaceutical. Collegium Pharmaceutical's average media sentiment score of 0.89 beat Rhythm Pharmaceuticals' score of 0.61 indicating that Collegium Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 13 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Collegium Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, RYTM or COLL? Rhythm Pharmaceuticals has a beta of 2.32, meaning that its stock price is 132% more volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.76, meaning that its stock price is 24% less volatile than the S&P 500. Which has better earnings and valuation, RYTM or COLL? Collegium Pharmaceutical has higher revenue and earnings than Rhythm Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M30.17-$184.68M-$4.35-14.27Collegium Pharmaceutical$631.45M1.38$48.15M$1.8614.58 SummaryCollegium Pharmaceutical beats Rhythm Pharmaceuticals on 10 of the 16 factors compared between the two stocks. Remove Ads Get Collegium Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COLL vs. The Competition Export to ExcelMetricCollegium PharmaceuticalPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$871.42M$6.32B$5.33B$7.57BDividend YieldN/A3.23%5.11%4.32%P/E Ratio11.696.7921.7317.81Price / Sales1.38225.93379.1994.60Price / Cash2.7665.6738.1534.64Price / Book4.535.866.464.00Net Income$48.15M$141.86M$3.20B$247.23M7 Day Performance6.73%8.98%6.54%7.26%1 Month Performance-7.94%-12.65%-8.55%-6.26%1 Year Performance-22.82%-11.99%10.33%-0.18% Collegium Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COLLCollegium Pharmaceutical4.0797 of 5 stars$27.12+1.5%$43.60+60.8%-22.8%$871.42M$631.45M11.69210Positive NewsGap DownRYTMRhythm Pharmaceuticals3.7043 of 5 stars$54.96+17.1%$73.31+33.4%+54.9%$3.47B$130.13M-12.69140High Trading VolumePTCTPTC Therapeutics3.884 of 5 stars$42.82-1.0%$63.77+48.9%+82.8%$3.38B$806.78M-7.211,410Short Interest ↑Positive NewsOGNOrganon & Co.4.798 of 5 stars$12.54-3.9%$20.80+65.9%-37.5%$3.23B$6.40B3.7610,000Short Interest ↓ZLABZai Lab2.4929 of 5 stars$28.81-9.3%$47.37+64.4%+113.9%$3.16B$398.99M-10.401,950News CoverageGap DownHigh Trading VolumeACLXArcellx1.9881 of 5 stars$56.65-3.3%$110.67+95.4%+7.8%$3.11B$107.94M-79.7980Positive NewsHigh Trading VolumeRNAAvidity Biosciences2.2721 of 5 stars$25.48-4.1%$66.69+161.7%+11.6%$3.06B$10.90M-8.85190RAREUltragenyx Pharmaceutical4.5522 of 5 stars$32.14-0.9%$92.79+188.7%-17.6%$3.02B$560.23M-5.071,310Positive NewsGap DownAKROAkero Therapeutics4.3059 of 5 stars$35.97-2.1%$76.29+112.1%+75.3%$2.86BN/A-9.5930Gap DownHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730SWTXSpringWorks Therapeutics2.0634 of 5 stars$36.99-5.4%$73.20+97.9%-11.6%$2.77B$191.59M-10.63230Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies RYTM Competitors PTCT Competitors OGN Competitors ZLAB Competitors ACLX Competitors RNA Competitors RARE Competitors AKRO Competitors MOR Competitors SWTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COLL) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredThis story is about to go viralThis Story Could Go Viral as Soon as May 31 Quietly, towns like Shreveport, Louisiana and Fort Worth, Texas...Stansberry Research | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Collegium Pharmaceutical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Collegium Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy COLL Stock Free COLL Stock Alerts